title: Tei index in adult patients submitted to adriamycin chemotherapy: failure to predict early systolic dysfunction. Diagnosis of adriamycin cardiotoxicity.
abstract: OBJECTIVE
  This study prospectively assessed whether Tei index is predictive of early systolic dysfunction in adults undergoing adriamycin treatment.
  
  
  RESULTS
  Left ventricular ejection fraction (LVEF) was obtained by radionuclide ventriculography at baseline and after treatment. Tei index was evaluated by echocardiography at baseline, at an intermediary cycle and at the end of chemotherapy. Fifty-five predominantly female patients (91%) with breast cancer (80%) and without known cardiac disease were evaluated. After treatment (adriamycin dose of 304 +/- 47 mg/m(2)), systolic dysfunction (final LVEF < 50%) occurred in eight patients (14%). Baseline, intermediate or variation of Tei index were not accurate to predict early systolic dysfunction ("c" statistics < or = 0.60). Baseline Tei index > 0.39, for example, had a sensitivity of 75%, specificity of 55%, positive predictive value of 22% and negative predictive value of 93%.
  
  
  CONCLUSIONS
  Tei index does not appear to be a useful tool for detection of early adriamycin cardiotoxicity in adults.
authors.affiliation: Division of Cardiology, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350/2060, Porto Alegre, RS 90035-003, Brazil.
authors.forename: Luis E
authors.initials: LE
authors.lastname: Rohde
authors.forename: Alexandre
authors.initials: A
authors.lastname: Baldi
authors.forename: Cristiane
authors.initials: C
authors.lastname: Weber
authors.forename: Guilherme
authors.initials: G
authors.lastname: Geib
authors.forename: Nicolle Gollo
authors.initials: NG
authors.lastname: Mazzotti
authors.forename: Marlon
authors.initials: M
authors.lastname: Fiorentini
authors.forename: Murilo
authors.initials: M
authors.lastname: Roggia
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Pereira
authors.forename: Nadine
authors.initials: N
authors.lastname: Clausell
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D015331:Cohort Studies; D004317:Doxorubicin / Q000009:adverse effects*; D015150:Echocardiography, Doppler; D005260:Female; D006352:Heart Ventricles / Q000000981:diagnostic imaging; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012372:ROC Curve; D011859:Radiography; D015635:Radionuclide Ventriculography; D012680:Sensitivity and Specificity; D013318:Stroke Volume; D013599:Systole; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000503:physiopathology; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin